LINTONPHARM
1.12.2021 14:02:14 CET | Business Wire | Press release
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847 ), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
“The initiation of our Phase 1 trial of catumaxomab for the treatment of NMIBC is an important step in our clinical program evaluating catumaxomab as targeted therapy in a broad range of cancers”, said Robert Li, PH.D., DABT, Co-founder and CEO of LintonPharm. “Patients with NMIBC BCG failure need new therapies due to the limitations of current treatments which bring poor prognosis, such as high rates of tumor recurrence, bladder dysfunction and lifelong intervention. Based on encouraging pre-clinical data and clinical experience with patients who’ve received catumaxomab in the past through the compassionate use program, we are hopeful that catumaxomab will be a very promising immunotherapy candidate for patients with NMIBC BCG failure.”
A recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC. It is noted that catumaxomab was well tolerated and presented promising performance in tumor control [1] . Based on the data and the developmental potential, catumaxomab could provide a feasible, safe, and efficacious therapy for NMIBC patients, if approved.
Bladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 percent are diagnosed as NMIBC [2][3] . Currently, the mainstay treatments of NMIBC include transurethral resection, chemotherapy and intravesical BCG [3] .
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. This bispecific antibody binds to a transmembrane glycoprotein on the tumor cell--the epithelial cell adhesion molecule (EpCAM)--and CD3 on the T cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab destroys tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models.
Recently, catumaxomab was authorized by regulatory authorities in China, Taiwan (China) and South Korea to conduct a global Phase 3 clinical trial for treating patients with advanced gastric cancer (clinicaltrials.gov: NCT04222114 ).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. The leading molecule, catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. For more information, please visit www.lintonpharm.com .
[1]. Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H (2021). First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunology, Immunotherapy. http://doi.org/10.1007/s00262-021-02930-7 |
[2]. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/ |
[3]. Kamat AM, Hahn NM, Efstathiou JA, et al. (2016) Bladder cancer. Lancet 2016. 388: 2796-810. http://dx.doi.org/10.1016/S0140-6736(16)30512-8 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005307/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Textron Aviation Opens New Melbourne Service Facility at Essendon Fields Airport, Expanding Support for Cessna, Beechcraft and Hawker Customers in APAC5.5.2026 17:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced its new service facility at Essendon Fields Airport in Melbourne is now open for customers, expanding factory-direct support for Cessna, Beechcraft and Hawker customers across Australia and the Asia-Pacific region. The purpose-built facility strengthens Textron Aviation’s global service network and reflects the company’s long-term commitment to expanding capacity and enhancing customer support throughout aircraft ownership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505135152/en/ Textron Aviation opens new Melbourne service facility at Essendon Fields airport, expanding support for Cessna, Beechcraft and Hawker customers in APAC “We’ve supported customers in Australia for decades, and we continue to invest where our customers tell us they need more capacity and faster access to factory direct expertise,” said Brian Rohloff, senior vice presiden
Doha Debates Podcast Examines the Global Questions Shaping Society5.5.2026 16:37:00 CEST | Press release
Weekly Tuesday releases from January 6 through June 2 extend conversations from Doha Debates’ flagship debates and global town halls Qatar Foundation’s Doha Debates continues the rollout of its weekly Doha Debates Podcast episodes, airing every Tuesday through June 2. Since launching on January 6, the season has brought leading global thinkers into direct conversation on the defining questions of our time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505299576/en/ Doha Debates podcast examines the global questions shaping society. Weekly Tuesday releases from January 6 through June 2 extend conversations from Doha Debates’ flagship debates and global town halls. (Photo: AETOSWire) The Doha Debates Podcast extends themes first explored in Doha Debates’ flagship debates and town halls, offering deeper, sustained exchanges that connect disciplines, regions and worldviews through open, truth-seeking dialogue. The latest epi
INRIX Unveils Global Standard for Traffic Signal Intelligence5.5.2026 16:34:00 CEST | Press release
Latest updates to INRIX Signal Analytics deliver expanded scale, confidence, and performance insight for cities worldwide INRIX, a global leader in transportation analytics and mobility intelligence, today announced a series of major updates to its award-winning Signal AnalyticsTM platform. These updates deliver unprecedented scale, statistical confidence, and flexibility by combining INRIX’s proven signal performance methodology with newly integrated traffic data, creating the most comprehensive, data-richsignal analytics solution to date. “INRIX Signal Analytics saves hours of monitoring every week by identifying where problems exist and enabling data-driven decisions that improve efficiency and safety at our intersections. It has been a valuable tool for optimizing our signal operations,” said Aaron M Torres, Traffic Operations Manager, Osceola County, Florida. With these updates, transportation agencies can now monitor, diagnose, and improve signalized intersections without install
Convatec’s Advanced Wound Care Innovation Leads the Industry at European Wound Management Association (EWMA) 20265.5.2026 16:11:00 CEST | Press release
Convatec will showcase new clinical and real‑world evidence across next‑generation foam technology, nitric oxide‑generating dressings, and Wound HygieneConvatec-sponsored scientific symposia to spotlight patient-centred innovation supported by robust in-vitro and clinical data enabling HCPs to deliver better outcomesConvatec to unveil Aquacel™ ConvaFiber™ in its European debut ahead of scale-up later this year Convatec, a leading medical products and technology company focused on chronic condition management, takes to the stage to showcase the breadth, depth and momentum behind its Advanced Wound Care innovation pipeline at the European Wound Management Association (EWMA) 2026 conference in Bremen, Germany, from 6–8 May 2026. Convatec’s industry-leading Advanced Wound Care innovation is supported by compelling new data from randomised controlled trials (RCTs) and real-world studies, with 13 abstracts accepted for publication and presentation at EWMA evaluating outcomes in hard-to-heal
Laserfiche Recognized as a Leader in 2026 Gartner® Magic Quadrant™ for Document Management5.5.2026 16:00:00 CEST | Press release
Laserfiche named a Leader for the second consecutive time based on its Completeness of Vision and Ability to Execute Laserfiche — the leading SaaS provider of intelligent content management — has been positioned as a Leader in the 2026 Magic Quadrant for Document Management. Laserfiche believes this recognition underscores the company’s commitment to empowering organizations to transform complex, operational business processes through AI-powered content management. “It’s incredible to see Laserfiche recognized during the same week as our annual Empower conference, where we announced our latest agentic AI capabilities,” said Thomas Phelps, senior vice president of corporate strategy and chief information officer at Laserfiche. “We believe being positioned as a Leader — and receiving the highest overall rating among 16 vendors in Gartner Peer Insights, with a 4.7 out of 5.0 based on over 1,300 reviews as of April 30, 2026 — reflects our relentless focus on product innovation and deliveri
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom